Business Wire

Jetcraft Releases 5-year Pre-Owned Market Forecast Enriched With Customer Insights

17.11.2020 15:00:00 EET | Business Wire | Press release

Share

Jetcraft, the world leader in business jet sales and acquisitions, is releasing a 5-Year Pre-Owned Business Aviation Market Forecast – including, for the first time, trends from the company’s own past transactional data and customer insights.

The latest forecast predicts pre-owned transaction volume and value will recover to steady growth during the five-year period, in spite of the challenges this year, reaching 2,271 transactions worth $11.1B annually by 2024.

Jahid Fazal-Karim, Owner and Chairman of the Board at Jetcraft, says: “Covid-19 has affected many industries, including our own. However, business aviation has started to recover and the reduction in commercial flight activity provides a real opportunity for the sector to further expand its customer base and secure long-term prosperity.

“For this year’s forecast we’ve decided to focus our predictions solely on the pre-owned market, a particular area of strength for Jetcraft and one that isn’t often included in other industry reports. Our forecast shows business aviation has begun to stabilize from the effect of the pandemic, and we expect to see 10,183 pre-owned transactions worth $48.8B in value over the next five years.”

Jetcraft’s forecast highlights trends in international trade activity that bode well for industry growth. Despite temporarily reduced activity in 2020, the World Trade Organization projects trade volume will rebound in 2021. Another key driver in business aviation transactions is the increase in the number of ultra-high net worth individuals (UHNWIs), which is set to grow by 5% per annum until 2024.

Fazal-Karim continues: “Our previous forecasts predicted a downturn. Although it has taken place sooner than we thought, we were prepared and, as a result, are in a stronger position than in 2008. We have seen our industry quickly regain momentum and I’m confident in its recovery, particularly with more first-time buyers realizing the value of business aviation, and the addition of new platforms which continue to improve accessibility.”

Drawing upon nearly 60 years of industry knowledge, this is the first year that Jetcraft’s Market Forecast is incorporating past transactional data and customer insights, delivering a unique look at buyer behavior.

Fazal-Karim concludes: “We are forecasting a continued increase in Large Jet transactions, albeit at a slower pace than in previous years. Our Jetcraft transactional data shows Large Jets representing a strong share of purchases by younger buyers, and that High Net Worth buyer types, as compared to Corporate or Government buyer types, are more likely to invest in this aircraft segment. These trends truly demonstrate the potential of the Large Jet category, which remains poised for long-term growth.

“Predicting the future is certainly more challenging against the backdrop of the current climate, and I’m especially proud to be sharing our anticipated annual industry outlook again this year.”

Jetcraft’s complete 2020 5-year Pre-Owned Business Aviation Market Forecast is available to download at https://www.jetcraft.com/knowledge/market-forecast/.

ENDS

Report graphs, high-resolution images and interviews are available on request.

About Jetcraft

Jetcraft is the leader in international aircraft sales, marketing and ownership strategies, managing and maintaining over 20 regional offices globally. The company’s unparalleled success over more than 55 years in business aviation has earned it a world-class reputation, along with an exceptional customer base, a wide network of connections and one of the largest inventories within the industry.

For more information, please visit www.jetcraft.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

8020 Communications.
E-Mail: jetcraft@8020comms.com
Telephone: +44 (0)1483 447380

Michaela Wilkins
Email: mwilkins@8020comms.com
Telephone: +44 (0) 1483 366419.

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release

Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release

Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release

For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release

Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye